XTANDI Approved for Treatment of CRPC
On July 24th, 2018
Astellas Pharma US, Inc. and Pfizer Inc. are pleased to announce that XTANDI is now indicated for the treatment of castration-resistant prostate cancer (CRPC) patients.
Astellas Pharma US, Inc. and Pfizer Inc. are pleased to announce that XTANDI is now indicated for the treatment of castration-resistant prostate cancer (CRPC) patients.
No comments have been posted yet.